Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Supernus Pharmaceuticals from “Buy” to “Hold.” MarketBeat reports a consensus “Hold” rating, with four Buys, two Holds, and one Sell, and an average price target of $62.83.
• Supernus shares opened at $47.64, versus a 52-week range of $40.26 to $59.68; the company has a market capitalization of approximately $2.77 billion.
• Institutional interest has increased, with BlackRock and several other investment firms establishing or expanding positions in the specialty pharmaceutical company.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday.

SUPN has been the topic of several other reports. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Zacks Research raised Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Monday, April 27th. Finally, Cantor Fitzgerald boosted their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an "overweight" rating in a research note on Thursday, July 9th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Supernus Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $62.83.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $47.64 on Friday. The firm's 50 day moving average price is $46.17 and its 200-day moving average price is $48.93. The company has a market cap of $2.77 billion, a PE ratio of -24.81, a P/E/G ratio of 0.76 and a beta of 0.56. Supernus Pharmaceuticals has a 52-week low of $40.26 and a 52-week high of $59.68.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth $434,871,000. Rubric Capital Management LP acquired a new stake in Supernus Pharmaceuticals in the second quarter valued at approximately $21,908,000. Assenagon Asset Management S.A. acquired a new position in Supernus Pharmaceuticals during the 1st quarter valued at about $27,428,000. Woodline Partners LP increased its holdings in shares of Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company's stock valued at $60,398,000 after acquiring an additional 490,835 shares in the last quarter. Finally, Rice Hall James & Associates LLC acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $22,800,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source